Variable/event type/AEa | nsNSAID (n = 225b) | Celecoxib (n = 68b) | Off NSAIDc(n = 79) |
---|---|---|---|
Incidence, n (%) | |||
Patients with at least 1 AE of special interest | 2 (0.9) | 0 | 2 (2.5) |
GI | 0 | 0 | 1 (1.3) |
GI ulcer | 0 | 0 | 0 |
Complications of GI ulcer | 0 | 0 | 1 (1.3) |
Cardiovascular/cardiorenal | 2 (0.9) | 0 | 1 (1.3) |
Thromboembolic events | 0 | 0 | 0 |
New-onset or worsening hypertension | 2 (0.9) | 0 | 1 (1.3) |
Patients with at least 1 GI composite event | 73 (32.4) | 23 (33.8) | 17 (21.5) |
Abdominal pain | 39 (17.3) | 12 (17.6) | 6 (7.6) |
Nausea/vomiting | 31 (13.8) | 13 (19.1) | 8 (10.1) |
All other GI | 44 (19.6) | 11 (16.2) | 11 (13.9) |
Incidence rate (per 100 person-years), (95% CI) | |||
Total person-years | 267.6 | 68.0 | 74.6 |
Incidence rate of events of special interest | 0.7 (0–1.8) | 0 | 2.7 (0–6.4) |
GI | 0 | 0 | 1.3 (0–4.0) |
Gl ulcer | 0 | 0 | 0 |
Complications of GI ulcer | 0 | 0 | 1.3 (0–4.0) |
Cardiovascular/cardiorenal | 0.7 (0–1.8) | 0 | 1.3 (0–4.0) |
Thromboembolic events | 0 | 0 | 0 |
New-onset or worsening hypertension | 0.7 (0–1.8) | 0 | 1.3 (0–4.0) |
Incidence rate of GI composite events | 27.3 (21.0–33.5) | 33.8 (20.0–47.6) | 22.8 (12.0–33.6) |
Abdominal pain | 14.6 (10.0–19.1) | 17.6 (7.7–27.6) | 8.0 (1.6–14.5) |
Nausea/vomiting | 11.6 (7.5–15.7) | 19.1 (8.7–29.5) | 10.7 (3.3–18.2) |
All other GI | 16.4 (11.6–21.3) | 16.2 (6.6–25.7) | 14.7 (6.0–23.5) |